Article
Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma.
Cellular & molecular biology letters - 10 Apr 2024
Li Weisong, Zheng Chao, Xu Xi, Xia Yujie, Zhang Kai, Huang Ao, Zhang Xinyu, Zheng Yong, Chen Guofang, Zhang Shuyong
Abstract excerpt
BACKGROUND: Melanoma is the most lethal skin cancer characterized by its high metastatic potential. In the past decade, targeted and immunotherapy have brought revolutionary survival benefits to patients with advanced and metastatic melanoma, but these treatment responses are also heterogeneous and/or do not achieve durable responses. Therefore, novel therapeutic strategies for improving outcomes remain an unmet...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.